Skip to content
Axcess News – Lifestyle
Author:
Ascletis Pharma Inc.
Ascletis Announces Positive Topline Results from U.S. Phase II, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule GLP-1R Agonist ASC30 for Obesity
March 10, 2026
←
Previous Page
1
2